Posted by Michael Wonder on 28 Feb 2026
Pendopharm announces the commercialisation of Buccolam in Canada
27 February 2026 - Pendopharm is pleased to announce that Buccolam is now available in Canada.
The launch of Buccolam represents an important step in Pendopharm's strategic partnership with Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system disorders, headquartered in Düsseldorf, Germany.
